Federal lawsuits alleging that the blockbuster eczema and asthma drug Dupixent (dupilumab) masked or delayed diagnoses of cutaneous T-cell lymphoma have been consolidated into a new multidistrict litigation, MDL No. 3180, in the U.S. District Court for the District of New Jersey. The Judicial Panel on Multidistrict Litigation centralized the cases on June 4, 2026, assigning them to Judge Zahid N. Quraishi.

The lawsuits name Sanofi and Regeneron, the pharmaceutical companies behind one of the world’s best-selling medicines — Dupixent generated €15.7 billion (roughly $17 billion) in global sales in 2025 alone. Plaintiffs allege the companies failed to warn patients and doctors that cutaneous T-cell lymphoma can mimic eczema, and that treating undiagnosed lymphoma with Dupixent may mask the disease and delay a cancer diagnosis.

This article explains what the new MDL means, what the lawsuits actually allege, what the science does and does not show, and what patients who developed T-cell lymphoma after taking Dupixent should consider — including in Texas, where the drug’s massive prescription base means affected patients are likely in every major metro.

The New Dupixent MDL: What Was Decided

What the Lawsuits Allege

The core allegation is a failure to warn. Cutaneous T-cell lymphoma in its early stages can look almost identical to severe eczema — red, scaly, intensely itchy patches of skin. Plaintiffs contend that Sanofi and Regeneron knew or should have known that some portion of adults diagnosed with ‘eczema’ actually have early, undiagnosed CTCL, yet the companies did not warn prescribers to screen for lymphoma before starting treatment, particularly in adult-onset or treatment-resistant cases.

The complaints further allege that Dupixent can temporarily improve the visible skin symptoms of undiagnosed CTCL — masking the cancer while it progresses — and that the companies provided no guidance to discontinue the drug and investigate when a patient’s condition worsened in an atypical way. Published case series describe exactly that pattern: initial improvement on dupilumab followed by progression consistent with lymphoma. Observational database studies have reported higher rates of CTCL diagnoses among dupilumab-treated patients than untreated comparison groups, though it is important to be clear that no single study proves causation, and the science will be heavily contested in the MDL.

Why This Litigation Matters for Patients

Dupixent’s commercial success is precisely what gives this litigation its scale. Millions of patients worldwide have been prescribed the drug for atopic dermatitis, asthma, nasal polyps, and, more recently, COPD. Even if the alleged masking effect involves only a small fraction of adult eczema patients who in fact had early CTCL, the size of the treated population means the number of affected patients could be significant — and Texas, with its large metro populations, is home to many of them.

A delayed lymphoma diagnosis is not a technicality. CTCL caught early is often managed for years with skin-directed therapy; diagnosed late, it can require aggressive systemic treatment and carries a substantially worse prognosis. The difference between an early and a late diagnosis — measured in medical bills, treatment burden, and life expectancy — is the injury at the center of these cases.

MDL vs. Class Action: What Consolidation Actually Means

A multidistrict litigation is not a class action. Each plaintiff in MDL-3180 keeps an individual lawsuit, with their own medical history, their own diagnosis timeline, and their own damages. The MDL simply brings the cases before one judge for coordinated discovery and pretrial rulings, which prevents duplicated effort and inconsistent decisions while the common scientific and corporate-knowledge questions are worked out.

For patients, that structure matters in two ways. First, individual case value is preserved — a claimant with a long treatment delay and advanced disease is not averaged together with less severe cases. Second, early filers tend to be positioned for bellwether consideration and the earliest resolution discussions. New MDLs also tend to grow quickly once attorney advertising and physician awareness catch up; MDL-3180’s 26 cases as of July 1 are widely viewed as the beginning of the curve, not its peak.

What Patients Who Took Dupixent Should Know

The patients with potential claims in this litigation generally share a pattern: they were treated with Dupixent for eczema or atopic dermatitis — often adult-onset or unusually resistant to treatment — and were later diagnosed with cutaneous T-cell lymphoma, mycosis fungoides, or Sézary syndrome. If that describes you or a family member, the two most important steps are medical and documentary.

Medically, stay under the care of your oncologist and dermatologist, and do not change or stop any medication without your doctor’s guidance. Legally, the foundation of any claim is the paper trail: when the skin condition first appeared, when Dupixent was prescribed, how symptoms responded, and when the lymphoma was ultimately diagnosed. Pharmacy records, biopsy reports, and clinic notes establish that timeline, and it is worth gathering them now, while they are easy to obtain.

Timing also matters. Texas generally applies a two-year statute of limitations to product liability injury claims, and while discovery rules can extend that window when a connection between a drug and an injury was not reasonably knowable, waiting narrows options. Because the MDL is in its earliest stage, patients who investigate their claims now — before leadership appointments and bellwether selections are complete — preserve the widest range of choices.

A consultation costs nothing and commits you to nothing. An attorney experienced in pharmaceutical litigation can review your treatment timeline, tell you honestly whether the facts support a claim, and file in the MDL if they do.